Data Available From Cetuximab Study in First-Line Treatment of Advanced Pancreatic Cancer
ImClone and Bristol-Myers Squibb announced that a phase III study of cetuximab (Erbitux) plus gemcitabine (Gemzar) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.
ImClone and Bristol-Myers Squibb announced that a phase III study of cetuximab (Erbitux) plus gemcitabine (Gemzar) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.
Conducted by the Southwest Oncology Group (SWOG), the open-label, randomized study compared cetuximab plus gemcitabine to gemcitabine alone in more than 700 patients with pancreatic cancer in the first-line treatment setting. The study was conducted in centers throughout the United States and Canada. It was completed in a significantly shorter time than projected, providing a timely answer to an important research question. SWOG has informed ImClone and Bristol-Myers Squibb that the primary study endpoint of statistically improving overall survival was not met. The three partiesSWOG, ImClone, and Bristol-Myers Squibbwill engage in joint efforts to fully interpret these results.
"This study was designed to examine the phase II results we previously observed for Eribtux in patients with pancreatic cancer," stated Eric K. Rowinsky, MD, chief medical officer and senior vice president of ImClone. "We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with Erbitux including a pilot study of Erbitux and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer."
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
FDA Approves FoundationOne CDx for Capivasertib Combo in Breast Cancer
November 21st 2023Companion diagnostic designation for FoundationOne CDx may improve access to treatment with capivasertib plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer harboring select alterations.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
